Loading...

MGC Pharmaceuticals Limited

MGCLF•PNK
HealthcareDrug Manufacturers - Specialty & Generic
$0.27
$0.007(2.88%)

MGC Pharmaceuticals Limited (MGCLF) Stock Overview

Explore MGC Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for MGCLFStats details for MGCLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for MGCLFAnalyst Recommendations details for MGCLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.

CEO

Mr. Roby Reuven Zomer

Headquarters

1202 Hay Street, West Perth, WA

Founded

2017

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.